Comparison of the Toxicity Profile of PD-1 Versus PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Analysis of the Literature

Cancer - United States
doi 10.1002/cncr.31043
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

P2.01-82 Neutrophil-To-Lymphocyte Ratio Complements the Prognostic Ability of PD-L1 in Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Real-World Evidenceand Clinical Observations of the Treatment of Advanced Non-Small Cell Lung Cancer With PD-1/PD-L1 Inhibitors

Scientific Reports
Multidisciplinary
2019English

PD-1 and PD-L1 Expression in Molecularly Selected Non-Small-Cell Lung Cancer Patients

British Journal of Cancer
Cancer ResearchOncology
2014English

Anti-Pd-1/Pd-L1 Antibody Versus Conventional Chemotherapy for Previously-Treated, Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2017English

P3.09-05 Significance of the Expression of PD-L1/PD-1 by Tumoral and Immune Cells in Non-Small Cell Lung Cancer.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Design of PD-L1 Inhibitors for Lung Cancer

Bioinformation
2019English

Pharmacoeconomic Evaluation of PD-L1 Receptor Inhibitors for the Second Line Treatment of Metastatic Non-Small Cell Lung Cancer

Medical Technologies. Assessment and Choice
2018English

PD-1/PD-L1: A Novel Target for Immunotherapy in Patients With Advanced and Metastatic Non-Small Cell Lung Cancer

Medicinski podmladak
2018English

Quantitative and Pathologist-Read Comparison of the Heterogeneity of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer

Modern Pathology
Forensic MedicinePathology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy